666 related articles for article (PubMed ID: 34987749)
1. Do women with venous thromboembolism bleed more than men during anticoagulation? Data from the real-life, prospective START-Register.
Palareti G; Legnani C; Antonucci E; Cosmi B; Falanga A; Poli D; Mastroiacovo D; Pengo V; Ageno W; Testa S
Ther Adv Drug Saf; 2021; 12():20420986211062965. PubMed ID: 34987749
[TBL] [Abstract][Full Text] [Related]
2. Bleeding and thrombotic complications during treatment with direct oral anticoagulants or vitamin K antagonists in venous thromboembolic patients included in the prospective, observational START2-register.
Palareti G; Antonucci E; Legnani C; Mastroiacovo D; Poli D; Prandoni P; Tosetto A; Pengo V; Testa S; Ageno W;
BMJ Open; 2020 Nov; 10(11):e040449. PubMed ID: 33247017
[TBL] [Abstract][Full Text] [Related]
3. Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis.
Marik PE; Cavallazzi R
PLoS One; 2015; 10(11):e0143252. PubMed ID: 26587983
[TBL] [Abstract][Full Text] [Related]
4. Very elderly patients with venous thromboembolism on oral anticoagulation with VKAs or DOACs: Results from the prospective multicenter START2-Register Study.
Poli D; Antonucci E; Bertù L; Vignini E; Ruocco L; Mastroiacovo D; Paparo C; Pastori D; Testa S; Ageno W; Palareti G;
Thromb Res; 2019 Nov; 183():28-32. PubMed ID: 31536872
[TBL] [Abstract][Full Text] [Related]
5. Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention.
Wu C; Alotaibi GS; Alsaleh K; Linkins LA; McMurtry MS
Thromb Res; 2015 Feb; 135(2):243-8. PubMed ID: 25488466
[TBL] [Abstract][Full Text] [Related]
6. Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients.
Haas S; Ageno W; Weitz JI; Goldhaber SZ; Turpie AGG; Goto S; Angchaisuksiri P; Dalsgaard Nielsen J; Kayani G; Zaghdoun A; Farjat AE; Schellong S; Bounameaux H; Mantovani LG; Prandoni P; Kakkar AK
J Thromb Haemost; 2019 Oct; 17(10):1694-1706. PubMed ID: 31220403
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism : A Systematic Review and Meta-analysis.
Khan F; Tritschler T; Kimpton M; Wells PS; Kearon C; Weitz JI; Büller HR; Raskob GE; Ageno W; Couturaud F; Prandoni P; Palareti G; Legnani C; Kyrle PA; Eichinger S; Eischer L; Becattini C; Agnelli G; Vedovati MC; Geersing GJ; Takada T; Cosmi B; Aujesky D; Marconi L; Palla A; Siragusa S; Bradbury CA; Parpia S; Mallick R; Lensing AWA; Gebel M; Grosso MA; Thavorn K; Hutton B; Le Gal G; Fergusson DA; Rodger MA;
Ann Intern Med; 2021 Oct; 174(10):1420-1429. PubMed ID: 34516270
[TBL] [Abstract][Full Text] [Related]
8. On-treatment Comparative Effectiveness of Vitamin K Antagonists and Direct Oral Anticoagulants in GARFIELD-VTE, and Focus on Cancer and Renal Disease.
Haas S; Farjat AE; Pieper K; Ageno W; Angchaisuksiri P; Bounameaux H; Goldhaber SZ; Goto S; Mantovani L; Prandoni P; Schellong S; Turpie AGG; Weitz JI; MacCallum P; Cate HT; Panchenko E; Carrier M; Jerjes-Sanchez C; Gibbs H; Jansky P; Kayani G; Kakkar AK;
TH Open; 2022 Oct; 6(4):e354-e364. PubMed ID: 36452204
[No Abstract] [Full Text] [Related]
9. Case fatality of bleeding and recurrent venous thromboembolism during, initial therapy with direct oral anticoagulants: a systematic review.
Wu C; Alotaibi GS; Alsaleh K; Sean McMurtry M
Thromb Res; 2014 Sep; 134(3):627-32. PubMed ID: 25047174
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of direct oral anticoagulants versus low molecular weight heparins for venous thromboembolism treatment in patients with gastrointestinal malignancies.
Guan T; Laguna A; Soares A; Legasto CS; Block S; Saunders IM; Alvarez K; Pon T; Patel N; Mahajan A; Lee A
J Thromb Thrombolysis; 2023 Oct; 56(3):439-446. PubMed ID: 37421494
[TBL] [Abstract][Full Text] [Related]
12. Using oral anticoagulants among chronic kidney disease patients to prevent recurrent venous thromboembolism: A systematic review and meta-analysis.
Alhousani M; Malik SU; Abu-Hashyeh A; Poznanski NJ; Al-Hasan S; Roth DF; Alsharedi M; Mustafa B
Thromb Res; 2021 Feb; 198():103-114. PubMed ID: 33310644
[TBL] [Abstract][Full Text] [Related]
13. Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves.
Russo V; Carbone A; Attena E; Rago A; Mazzone C; Proietti R; Parisi V; Scotti A; Nigro G; Golino P; D'Onofrio A
Clin Ther; 2019 Dec; 41(12):2549-2557. PubMed ID: 31735436
[TBL] [Abstract][Full Text] [Related]
14. Case Fatality Rates of Recurrent Thromboembolism and Bleeding in Patients Receiving Direct Oral Anticoagulants for the Initial and Extended Treatment of Venous Thromboembolism: A Systematic Review.
Gómez-Outes A; Lecumberri R; Suárez-Gea ML; Terleira-Fernández AI; Monreal M; Vargas-Castrillón E
J Cardiovasc Pharmacol Ther; 2015 Sep; 20(5):490-500. PubMed ID: 25802423
[TBL] [Abstract][Full Text] [Related]
15. Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study.
Russo V; Attena E; Di Maio M; Mazzone C; Carbone A; Parisi V; Rago A; D'Onofrio A; Golino P; Nigro G
J Thromb Thrombolysis; 2020 Jan; 49(1):42-53. PubMed ID: 31385163
[TBL] [Abstract][Full Text] [Related]
16. Direct oral anticoagulants in patients with antiphospholipid syndrome: a cohort study.
Malec K; Broniatowska E; Undas A
Lupus; 2020 Jan; 29(1):37-44. PubMed ID: 31757182
[TBL] [Abstract][Full Text] [Related]
17. OC-13 - Safe and effective use of direct oral anticoagulants (DOAC) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism.
Ross JA; Miller M; Hernandez CR
Thromb Res; 2016 Apr; 140 Suppl 1():S173-4. PubMed ID: 27161685
[TBL] [Abstract][Full Text] [Related]
18. Editor's Choice - A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer.
Kirkilesis GI; Kakkos SK; Tsolakis IA
Eur J Vasc Endovasc Surg; 2019 May; 57(5):685-701. PubMed ID: 31097186
[TBL] [Abstract][Full Text] [Related]
19. Adverse Events Associated With the Addition of Aspirin to Direct Oral Anticoagulant Therapy Without a Clear Indication.
Schaefer JK; Errickson J; Li Y; Kong X; Alexandris-Souphis T; Ali MA; Decamillo D; Haymart B; Kaatz S; Kline-Rogers E; Kozlowski JH; Krol GD; Shankar SR; Sood SL; Froehlich JB; Barnes GD
JAMA Intern Med; 2021 Jun; 181(6):817-824. PubMed ID: 33871544
[TBL] [Abstract][Full Text] [Related]
20. DOACs vs Vitamin K Antagonists During Cardiac Rhythm Device Surgery: A Multicenter Propensity-Matched Study.
Creta A; Ventrella N; Earley MJ; Finlay M; Sporton S; Maclean E; Kanthasamy V; Lemos Silva Di Nubila BC; Ricciardi D; Calabrese V; Picarelli F; Hunter RJ; Lambiase PD; Schilling RJ; Grigioni F; Monkhouse C; Muthumala A; Moore P; Providencia R; Chow A
JACC Clin Electrophysiol; 2024 Jan; 10(1):121-132. PubMed ID: 37897463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
